The following information is disclosed in accordance with Rule 26 of the AIM Rules for Companies and was last updated on 5 April 2023. N4 Pharma Plc is incorporated in England (Registration Number 01435584). The Company’s principal country of operation is the United Kingdom.
- About N4 Pharma
- Board of Directors
- Corporate Governance and Director Responsibility
- AIM Securities information
- Details of other exchanges and Trading Platforms
The Company is not listed on any other exchanges or platforms.
- Details of any restrictions on the Transfer of AIM Securities:
There are no restrictions on the transfer of AIM securities.
- Details on UK City Code on Takeovers and Mergers:
The Company is subject to the City Code Takeovers and Mergers
AIM Securities Information
Number of AIM securities in issue – 233,780,349 (as at 5 April 2023) ordinary shares of 0.4p. No Ordinary Shares are held in treasury.
|Shareholder||Number of Shares Held||% of Issued Share Capital|
Percentage of AIM securities not in public hands – 7.32% (as at 5 April 2023)
The Company had previously included nominee account shareholdings in the table above and in the calculation for “shares not in public hands”. Having completed an analysis of the underlying beneficial shareholders to the nominee holdings, the Company has identified that there are no notifiable interests pursuant to AIM Rule 26 save for as included in the table above.
Nominated Adviser and Stockbroker
SP Angel Corporate Finance LLP
35 Maddox St
Neville Registrars Limited
18 Laurel Lane
71 Queen Victoria Street
Solicitors to the Company
DWF Law LLP
8 Frederick’s Place,
Corporate Governance and Director Responsibilities
It is the Board’s job to ensure that N4 Pharma Plc is managed for the long-term benefit of all shareholders, with effective and efficient decision-making. Corporate governance is an important part of that job, reducing risk and adding value to our business.
Read our Corporate Governance Statement of Compliance with the QCA Corporate Governance Code. This statement will be updated annually at the time of publication of the annual report and accounts. The statement was last updated on 24 March 2023.